Compare VRTS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTS | MGTX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1995 | 2018 |
| Metric | VRTS | MGTX |
|---|---|---|
| Price | $167.45 | $14.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $158.00 | $24.57 |
| AVG Volume (30 Days) | 112.2K | ★ 505.8K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | 18.24 | ★ 33.02 |
| EPS | ★ 7.72 | 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | $1.66 | N/A |
| P/E Ratio | $21.59 | ★ $11.52 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $121.61 | $6.62 |
| 52 Week High | $203.61 | $15.35 |
| Indicator | VRTS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 69.44 |
| Support Level | $161.58 | $7.04 |
| Resistance Level | $170.30 | $15.35 |
| Average True Range (ATR) | 3.97 | 0.66 |
| MACD | -0.52 | 0.21 |
| Stochastic Oscillator | 58.85 | 90.45 |
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.